Tiny in terms of size, huge in terms of impact: Nanoparticles represent the greatest hope for modern medicine. A hundred times smaller than a human cell, they make ideal “packages” to deliver active substances of all kinds. Within this area of drug delivery, the use of sophisticated nano-carriers should bring unprecedented advantages, providing greater bioavailability, opening new application channels, and enabling the highly targeted and precisely controlled release of medications.
Dr. Friedrich Wilhelm Steinweg
CEO of Nanohale AG
Nanohale aims to open entirely new modes of application for drugs which until now could only be delivered by conventional means, such as parenteral injection or infusion.
Nanohale develops proprietary nanoparticle-based carrier systems for pharmaceutical formulations.
The primary research and product development focus of Nanohale until now has been on proteins and peptides.
With the appointment of Dr. Brockmeyer, Nanohale brings on board a seasoned executive from the pharmaceutical industry with many years of experience in the strategic development and marketing of biosimilars.
